

Paola Rogliani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341783/publications.pdf>

Version: 2024-02-01

368
papers

8,814
citations

53794

45
h-index

79698

73
g-index

371
all docs

371
docs citations

371
times ranked

8914
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2832-2835.	7.1	497
2	Feasibility and Results of Awake Thoracoscopic Resection of Solitary Pulmonary Nodules. Annals of Thoracic Surgery, 2004, 78, 1761-1768.	1.3	244
3	β_2 -Agonist Therapy in Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 690-696.	5.6	221
4	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest, 2016, 149, 1181-1196.	0.8	206
5	Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. European Respiratory Journal, 2012, 40, 101-109.	6.7	179
6	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	4.1	159
7	Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 2015, 24, 451-461.	7.1	140
8	The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 2016, 117, 190-197.	2.9	136
9	Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine, 2017, 124, 6-14.	2.9	131
10	HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla, 2020, 96, 610-614.	0.6	130
11	Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 47-54.e1.	0.8	112
12	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2016, 40, 95-103.	2.6	112
13	Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews, 2020, 72, 218-252.	16.0	104
14	Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. European Respiratory Journal, 2018, 52, 1801586.	6.7	101
15	Asthma and comorbid medical illness. European Respiratory Journal, 2011, 38, 42-49.	6.7	98
16	Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respiratory Medicine, 2012, 106, 249-256.	2.9	89
17	Awake Thoracoscopic Biopsy of Interstitial Lung Disease. Annals of Thoracic Surgery, 2013, 95, 445-452.	1.3	89
18	COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. Genes, 2020, 11, 1010.	2.4	88

#	ARTICLE	IF	CITATIONS
19	Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 414-423.	2.5	80
20	Pharmacological characterization of the interaction between acclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , 2014, 745, 135-143.	3.5	80
21	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 552-563.	1.6	77
22	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 175-181.	1.6	73
23	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	3.6	71
24	Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in α_1 -Antitrypsin Deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 20, 441-447.	2.9	68
25	High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 509-516.	2.9	66
26	Adding a LAMA to ICS/LABA Therapy. <i>Chest</i> , 2019, 155, 758-770.	0.8	65
27	Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , 2017, 129, 117-123.	2.9	64
28	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	2.2	63
29	Effect of Lung Volume Reduction Surgery for Severe Emphysema on Right Ventricular Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 489-494.	5.6	60
30	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , 2017, 18, 26.	3.6	60
31	Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <i>Human Genomics</i> , 2020, 14, 29.	2.9	60
32	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 15-27.	2.6	57
33	HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. <i>Respiratory Medicine</i> , 2008, 102, 1753-1761.	2.9	54
34	Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311.	2.9	54
35	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 804-814.	2.9	54
36	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 148-158.	2.6	54

#	ARTICLE	IF	CITATIONS
37	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017, 129, 189-198.	2.9	54
38	Comorbidities of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 36-41.	2.6	53
39	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , 2018, 18, 70.	2.0	53
40	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016, Volume 11, 3007-3013.	2.3	52
41	Do we really need asthmaâ€“chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 977-983.	2.9	52
42	Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , 2016, 221, 1031-1038.	1.7	51
43	TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , 2020, 80, 449-458.	10.9	51
44	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017, 26, 160043.	7.1	50
45	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1133-1146.	2.4	47
46	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9.	2.6	47
47	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle <i>ex vivo</i> . <i>British Journal of Pharmacology</i> , 2020, 177, 1150-1163.	5.4	47
48	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , 2021, 9, 227.	4.4	47
49	α_1 -Antitrypsin deficiency and chronic respiratory disorders. <i>European Respiratory Review</i> , 2020, 29, 190073.	7.1	47
50	Defining Phenotypes in COPD: An Aid to Personalized Healthcare. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 381-388.	3.8	46
51	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 15-23.	2.6	46
52	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 940-951.	8.7	46
53	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000625.	6.7	46
54	Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 61, 101899.	2.6	46

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104.	3.6	45
56	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 452-463.	8.7	42
57	Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , 2020, 21, 286.	3.6	42
58	Biomarkers of lung damage associated with tobacco smoke in induced sputum. <i>Respiratory Medicine</i> , 2009, 103, 1592-1613.	2.9	41
59	Combined Pulmonary Fibrosis and Emphysema: 3D Time-resolved MR Angiographic Evaluation of Pulmonary Arterial Mean Transit Time and Time to Peak Enhancement. <i>Radiology</i> , 2010, 254, 601-608.	7.3	40
60	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 221-226.	2.6	40
61	Diabetes mellitus among outpatients with COPD attending a university hospital. <i>Acta Diabetologica</i> , 2014, 51, 933-940.	2.5	40
62	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 47-55.	2.6	40
63	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 733-744.	5.0	39
64	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 635-646.	5.0	39
65	The Challenges of Precision Medicine in COPD. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 345-355.	3.8	37
66	Acute exacerbations of COPD: risk factors for failure and relapse. <i>International Journal of COPD</i> , 2017, Volume 12, 2687-2693.	2.3	37
67	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 291-298.	2.3	36
68	Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 533-541.	2.4	36
69	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2016, 76, 1257-1270.	10.9	36
70	The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 325-331.	2.6	35
71	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , 2017, Volume 12, 3469-3485.	2.3	35
72	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , 2019, 154, 86-92.	2.9	35

#	ARTICLE	IF	CITATIONS
73	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , 2019, 153, 3-13.	2.9	35
74	Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , 2021, 176, 106236.	2.9	35
75	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. <i>COPD Research and Practice</i> , 2015, 1, .	0.7	33
76	An update on bronchodilators in Phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1489-1501.	4.1	32
77	Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 775-781.	1.8	32
78	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. <i>International Journal of COPD</i> , 2018, Volume 13, 3115-3130.	2.3	32
79	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101841.	2.6	32
80	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , 2015, 761, 383-390.	3.5	31
81	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , 2021, 58, 2004233.	6.7	31
82	Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. <i>Respiratory Medicine</i> , 2008, 102, 321-327.	2.9	30
83	Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. <i>Drugs</i> , 2015, 75, 1575-1585.	10.9	30
84	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , 2018, 19, 65.	3.6	30
85	Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 693-708.	2.5	30
86	Treating systemic effects of COPD. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 544-550.	8.7	29
87	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , 2017, 77, 721-732.	10.9	29
88	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 143-152.	2.5	29
89	HLA-DP-unrestricted TNF- α release in beryllium-stimulated peripheral blood mononuclear cells. <i>European Respiratory Journal</i> , 2002, 20, 1174-1178.	6.7	28
90	Inhaled corticosteroids for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2489-2499.	1.8	28

#	ARTICLE	IF	CITATIONS
91	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. Drug Safety, 2016, 39, 501-508.	3.2	28
92	Pharmacological treatments in asthma-affected horses: A pairwise and network meta-analysis. Equine Veterinary Journal, 2017, 49, 710-717.	1.7	28
93	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. European Journal of Pharmacology, 2017, 812, 147-154.	3.5	28
94	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	2.9	28
95	Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs of Today, 2012, 48, 785.	1.1	28
96	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulmonary Pharmacology and Therapeutics, 2009, 22, 478-482.	2.6	27
97	Chronic obstructive pulmonary disease and diabetes. COPD Research and Practice, 2015, 1, .	0.7	27
98	Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2017, 11, 239-253.	2.5	27
99	Does bronchoscopy help the diagnosis in COVID-19 infection?. European Respiratory Journal, 2020, 56, 2001619.	6.7	27
100	Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. Expert Review of Respiratory Medicine, 2021, 15, 561-568.	2.5	27
101	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofaa588.	0.9	27
102	Pharmacological treatment and current controversies in COPD. F1000Research, 2019, 8, 1533.	1.6	27
103	Identification of HLA-DRPhe ²⁴⁷ as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGLu ²⁶⁹ . Respiratory Research, 2005, 6, 94.	3.6	26
104	Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. Drugs, 2014, 74, 1983-1992.	10.9	26
105	Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2014, 15, 961-977.	1.8	26
106	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. Respiratory Medicine, 2016, 117, 150-153.	2.9	26
107	Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Review of Respiratory Medicine, 2018, 12, 261-264.	2.5	26
108	Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opinion on Investigational Drugs, 2019, 28, 827-833.	4.1	26

#	ARTICLE	IF	CITATIONS
109	Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2008, 2, 75-93.	2.6	25
110	Tiotropium formulations and safety: a network meta-analysis. Therapeutic Advances in Drug Safety, 2017, 8, 17-30.	2.4	25
111	Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Safety, 2021, 44, 273-290.	3.2	25
112	How does race/ethnicity influence pharmacological response to asthma therapies?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 435-446.	3.3	24
113	The future of bronchodilation: looking for new classes of bronchodilators. European Respiratory Review, 2019, 28, 190095.	7.1	24
114	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. Vaccines, 2021, 9, 341.	4.4	24
115	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. Heliyon, 2020, 6, e05143.	3.2	23
116	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respiratory Medicine, 2020, 171, 106114.	2.9	23
117	Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 2305-2316.	1.8	23
118	Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. Respiratory Medicine, 2013, 107, 1417-1422.	2.9	22
119	Cardiovascular disease in patients with COPD. Lancet Respiratory Medicine, the, 2015, 3, 593-595.	10.7	22
120	The effect of indacaterol during an acute exacerbation of COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 630-634.	2.6	21
121	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respiratory Medicine, 2015, 109, 1019-1025.	2.9	21
122	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 156, 78-84.	2.9	21
123	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2019, 56, 39-50.	2.6	21
124	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs, 2020, 80, 1799-1809.	10.9	21
125	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. Journal of Clinical Medicine, 2021, 10, 1607.	2.4	21
126	Serum CA 15-3 is increased in pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2009, 26, 54-63.	0.2	21

#	ARTICLE	IF	CITATIONS
127	Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. <i>Current Opinion in Pharmacology</i> , 2012, 12, 300-308.	3.5	20
128	Brain Natriuretic Peptide Protects against Hyperresponsiveness of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell-Dependent Mechanism. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 493-501.	2.9	20
129	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , 2015, 131, 44-50.	4.3	20
130	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <i>Current Opinion in Pharmacology</i> , 2018, 40, 34-38.	3.5	20
131	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 185-194.	2.6	20
132	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 1-8.	5.6	20
133	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 744-750.	1.1	20
134	Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. <i>Diabetes Care</i> , 2021, 44, 2149-2157.	8.6	20
135	Metabolic syndrome and risk of pulmonary involvement. <i>Respiratory Medicine</i> , 2010, 104, 47-51.	2.9	18
136	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 573-581.	4.1	18
137	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , 2019, 36, 3291-3298.	2.9	18
138	A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1079-1085.	2.5	18
139	Inhaled long-acting muscarinic antagonists in asthma – A narrative review. <i>European Journal of Internal Medicine</i> , 2021, 85, 14-22.	2.2	18
140	Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , 2021, 172, 105801.	7.1	18
141	Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1473-1482.	4.1	17
142	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 526-532.	1.6	17
143	Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 51, 1-9.	2.6	17
144	Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , 2020, 177, 4750-4765.	5.4	17

#	ARTICLE	IF	CITATIONS
145	The latest on the role of LAMAs in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1288-1291.	2.9	17
146	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 52-60.	3.5	17
147	The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. <i>International Journal of COPD</i> , 2021, Volume 16, 257-279.	2.3	17
148	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 111-121.	3.8	17
149	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 291-302.	3.2	17
150	Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. <i>Respiratory Medicine</i> , 2013, 107, 848-853.	2.9	16
151	Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 665-671.	2.5	16
152	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101828.	2.6	16
153	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101855.	2.6	16
154	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 215-226.	1.6	16
155	<p>Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 233-253.	3.2	16
156	Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 323-332.	3.1	16
157	Use of Thiols in the Treatment of COVID-19: Current Evidence. <i>Lung</i> , 2021, 199, 335-343.	3.3	16
158	Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 73-79.	0.8	15
159	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. <i>International Journal of Mycobacteriology</i> , 2016, 5, 244-247.	0.6	15
160	Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 429-435.	2.4	15
161	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	1.8	15
162	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 603-614.	3.8	15

#	ARTICLE	IF	CITATIONS
163	Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , 2019, 156, 47-52.	2.9	15
164	Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 33, 1-10.	2.6	14
165	Influence of ethnicity on response to asthma drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1089-1097.	3.3	14
166	QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1079-1090.	1.8	14
167	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 43-54.	2.5	14
168	Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave. <i>Respiratory Investigation</i> , 2021, 59, 661-665.	1.8	14
169	Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: <i>formeâ€fruste</i> of Churgâ€Strauss syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1389-1390.	5.7	13
170	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 28-37.	2.6	13
171	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 589-596.	2.4	13
172	Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 517-520.	3.3	13
173	The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , 2021, 9, 1281.	3.2	13
174	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 737-750.	1.8	13
175	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. <i>Respiratory Medicine</i> , 2013, 107, 2014-2021.	2.9	12
176	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. <i>EBioMedicine</i> , 2017, 19, 14-15.	6.1	12
177	Bronchodilator therapy for chronic cough. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 47, 88-92.	2.6	12
178	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , 2018, 832, 114-119.	3.5	12
179	Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , 2019, 151, 43-48.	2.9	12
180	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988812.	2.6	12

#	ARTICLE	IF	CITATIONS
181	<p></p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p></p>. International Journal of COPD, 2020, Volume 15, 1269-1285.	2.3	12
182	<p></p>Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease</p></p>. Journal of Experimental Pharmacology, 2020, Volume 12, 559-574.	3.2	12
183	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. Drugs, 2022, 82, 1-13.	10.9	12
184	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. Microorganisms, 2022, 10, 268.	3.6	12
185	Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema1. European Journal of Cardio-thoracic Surgery, 1998, 14, 33-39.	1.4	11
186	Thoracoscopic Reduction Pneumoplasty for Severe Emphysema: Do Pleural Adhesions Affect Outcome?. Thoracic and Cardiovascular Surgeon, 1999, 47, 288-292.	1.0	11
187	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. Pulmonary Pharmacology and Therapeutics, 2009, 22, 522-525.	2.6	11
188	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602345.	6.7	11
189	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	2.6	11
190	Anaphylaxis and intimate behaviour. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 350-355.	2.3	11
191	Clinical effect of corticosteroids in asthmaâ€affected horses: A quantitative synthesis. Equine Veterinary Journal, 2018, 50, 594-601.	1.7	11
192	<p></p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 43-53.	2.5	11
193	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	4.1	11
194	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organization Journal, 2019, 12, 100081.	3.5	11
195	The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. Respiratory Medicine, 2022, 200, 106915.	2.9	11
196	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine, 2013, 107, 107-111.	2.9	10
197	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 529-539.	3.1	10
198	The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. Pharmacological Research, 2016, 111, 659-667.	7.1	10

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1101-1111.	3.3	10
200	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 2019, 14, 25.	1.5	10
201	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Review of Clinical Pharmacology, 2020, 13, 977-990.	3.1	10
202	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy, 2021, 22, 611-620.	1.8	10
203	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, 2021, Volume 15, 363-374.	3.2	10
204	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. Monaldi Archives for Chest Disease, 2022, , .	0.6	10
205	Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 2022, 88, 3657-3673.	2.4	10
206	LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. Evidence-Based Medicine, 2016, 21, 222-222.	0.6	9
207	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2016, 17, 977-988.	1.8	9
208	An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2017, 18, 973-988.	1.8	9
209	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 641-647.	1.6	9
210	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 239-245.	3.3	9
211	Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 546-554.	1.3	9
212	Disease awareness in patients with COPD: measurement and extent. International Journal of COPD, 2019, Volume 14, 1-11.	2.3	9
213	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. Lung, 2018, 196, 707-713.	3.3	9
214	Drug interaction and chronic obstructive respiratory disorders. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100009.	3.6	9
215	Happy hypoxemia, or blunted ventilation?. Respiratory Research, 2021, 22, 4.	3.6	9
216	Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine, 2021, 15, 1159-1168.	2.5	9

#	ARTICLE	IF	CITATIONS
217	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , 2021, 188, 106611.	2.9	9
218	New Treatments for COPD in the Elderly. <i>Current Pharmaceutical Design</i> , 2014, 20, 5968-5982.	1.9	9
219	Beyond Dual Bronchodilation – Triple Therapy, When and Why. <i>International Journal of COPD</i> , 2022, Volume 17, 165-180.	2.3	9
220	Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. <i>European Annals of Allergy and Clinical Immunology</i> , 2016, 48, 61-4.	1.0	9
221	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 595-607.	5.0	8
222	Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 35-41.	3.1	8
223	Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. <i>Journal of Thoracic Disease</i> , 2016, 8, 3704-3710.	1.4	8
224	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	8
225	Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1643-1646.	3.8	8
226	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β_2 -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , 2019, 5, 117-126.	2.2	8
227	Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2178-2180.	2.8	8
228	Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 59-70.	2.5	8
229	The complex care of severe emphysema: role of awake lung volume reduction surgery. <i>Annals of Translational Medicine</i> , 2015, 3, 108.	1.7	8
230	The future of inhalation therapy in chronic obstructive pulmonary disease. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100092.	3.6	8
231	The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. <i>European Respiratory Review</i> , 2022, 31, 210196.	7.1	8
232	Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 156-157.	2.6	7
233	Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , 2016, 44, 387-388.	1.7	7
234	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793.	3.8	7

#	ARTICLE	IF	CITATIONS
235	Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2016, 39, 48-53.	2.6	7
236	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. Pulmonary Pharmacology and Therapeutics, 2018, 49, 88-94.	2.6	7
237	Is ICS+LAMA an alternative option to treat patients with COPD?. Lancet Respiratory Medicine, 2018, 6, 316-317.	10.7	7
238	Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 310-311.	1.6	7
239	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. Respiration, 2018, 96, 543-551.	2.6	7
240	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	1.3	7
241	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101883.	2.6	7
242	The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology, 2020, 13, 865-874.	3.1	7
243	Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2021, 100, 291-297.	2.6	7
244	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opinion on Drug Delivery, 2021, 18, 891-906.	5.0	7
245	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102050.	2.6	7
246	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells, 2022, 11, 1797.	4.1	7
247	Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 107-115.	1.8	6
248	Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	1.7	6
249	Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase. Rejuvenation Research, 2016, 19, 79-89.	1.8	6
250	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "œreal life"? Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 535.	3.8	6
251	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	2.4	6
252	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. Human Vaccines and Immunotherapeutics, 2018, 14, 1438-1441.	3.3	6

#	ARTICLE	IF	CITATIONS
253	The prognostic role of Genderâ€Ageâ€Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , 2019, 13, 166-173.	1.6	6
254	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1657-1658.	2.9	6
255	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	2.4	6
256	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , 2020, 41, 2671-2674.	1.9	6
257	Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2169-2183.	1.8	6
258	<p><p>Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy<p><p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 261-271.	0.7	6
259	What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. <i>Respiratory Medicine</i> , 2020, 166, 105937.	2.9	6
260	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7132.	4.1	6
261	Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. <i>Drugs of Today</i> , 2015, 51, 469.	1.1	6
262	Benralizumab for the treatment of asthma. <i>Drugs of Today</i> , 2017, 53, 633.	1.1	6
263	Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in âœœreal lifeâœ¿. <i>European Annals of Allergy and Clinical Immunology</i> , 2018, 50, 283.	1.0	6
264	Synergy across the drugs approved for the treatment of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.9	6
265	Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 73-74, 102125.	2.6	6
266	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 565-577.	3.4	6
267	The clinical use of regenerative therapy in COPD. <i>International Journal of COPD</i> , 2014, 9, 1389.	2.3	5
268	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , 2014, 108, 307-313.	2.9	5
269	Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1621-1622.	2.9	5
270	Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 627-636.	1.4	5

#	ARTICLE	IF	CITATIONS
271	What Could the Role of Can f 5 Allergen Be in Dog- Sensitized Patients in "Real Life"? Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 397-398.	1.3	5
272	Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. Journal of Thoracic Disease, 2018, 10, S2754-S2762.	1.4	5
273	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opinion on Pharmacotherapy, 2018, 19, 2043-2053.	1.8	5
274	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opinion on Investigational Drugs, 2020, 29, 723-738.	4.1	5
275	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	3.8	5
276	Quasibar minimalist lung volume reduction surgery. European Journal of Cardio-thoracic Surgery, 2021, 60, 598-606.	1.4	5
277	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. Journal of Clinical Sleep Medicine, 2021, 17, 2383-2391.	2.6	5
278	Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. Rhinology, 2021, 59, 0-0.	1.3	5
279	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. Expert Review of Respiratory Medicine, 2021, 15, 1473-1481.	2.5	5
280	Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 1089-1096.	0.6	5
281	How many systemic reactions to skin prick tests could be preventable in defined conditions?. Annals of Allergy, Asthma and Immunology, 2016, 116, 174.	1.0	4
282	Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. Expert Opinion on Pharmacotherapy, 2017, 18, 833-835.	1.8	4
283	Use of mucolytics in COPD: A Delphi consensus study. Respiratory Medicine, 2020, 175, 106190.	2.9	4
284	Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100010.	3.6	4
285	Mepolizumab Effectiveness and Allergic Status in Real Life. International Archives of Allergy and Immunology, 2021, 182, 311-318.	2.1	4
286	Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. Clinical Respiratory Journal, 2021, 15, 237-243.	1.6	4
287	Management of COPD patients during COVID: difficulties and experiences. Expert Review of Respiratory Medicine, 2021, 15, 1025-1033.	2.5	4
288	The Future of Bronchodilators in COPD and Asthma. Archivos De Bronconeumologia, 2022, 58, 107-108.	0.8	4

#	ARTICLE	IF	CITATIONS
289	Disputes over the production and dissemination of misinformation in the time of COVID-19. Respiratory Medicine, 2021, 182, 106380.	2.9	4
290	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. Expert Review of Respiratory Medicine, 2021, 15, 579-581.	2.5	4
291	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. Respiratory Medicine, 2021, 189, 106639.	2.9	4
292	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases, 2020, 5, 18.	0.2	4
293	Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies. Journal of Experimental Pharmacology, 2022, Volume 14, 1-5.	3.2	4
294	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. Expert Opinion on Pharmacotherapy, 2022, 23, 917-927.	1.8	4
295	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opinion on Pharmacotherapy, 2022, 23, 1205-1216.	1.8	4
296	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 . Immunology: in Practice, 2017, 5, 873.	3.8	3
297	In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids. Evidence-Based Medicine, 2017, 22, 183-184.	0.6	3
298	Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. Respiratory Medicine, 2019, 153, 68-75.	2.9	3
299	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. Journal of Cardiovascular Medicine, 2021, 22, 190-196.	1.5	3
300	Comparative studies of dual bronchodilation in COPD. Monaldi Archives for Chest Disease, 2021, 91, .	0.6	3
301	Mortality in ETHOS: A Question of "Power". American Journal of Respiratory and Critical Care Medicine, 2021, 203, 926-927.	5.6	3
302	Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected. European Annals of Allergy and Clinical Immunology, 2022, 54, 99.	1.0	3
303	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. Expert Review of Respiratory Medicine, 2022, 16, 357-365.	2.5	3
304	Which LABA/LAMA should be chosen in COPD patients in real life?. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102076.	2.6	3
305	Editorial overview: Respiratory: Pulmonary pharmacology "The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. Current Opinion in Pharmacology, 2021, 60, 54-58.	3.5	3
306	Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. European Annals of Allergy and Clinical Immunology, 2019, 51, 44.	1.0	3

#	ARTICLE	IF	CITATIONS
307	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. Monaldi Archives for Chest Disease, 2021, , .	0.6	3
308	Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a correct biologic prescription. Journal of Biological Regulators and Homeostatic Agents, 2020, 34, 315-318.	0.7	3
309	Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. Immunology and Allergy Clinics of North America, 2022, , .	1.9	3
310	Dog allergen immunotherapy and allergy to furry animals. Annals of Allergy, Asthma and Immunology, 2016, 116, 590.	1.0	2
311	Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy, 2017, 3, 45-57.	2.2	2
312	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 49, 20-26.	2.6	2
313	LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. Respiration, 2018, 96, 370-381.	2.6	2
314	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opinion on Emerging Drugs, 2018, 23, 185-199.	2.4	2
315	Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. Respiratory Medicine and Research, 2020, 78, 100791.	0.6	2
316	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Review of Respiratory Medicine, 2020, 14, 621-635.	2.5	2
317	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 215-223.	1.6	2
318	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	2
319	Radiological pitfalls associated with the diagnosis of usual interstitial pneumonia pattern on high-resolution computed tomography and associated findings: experience from a single Italian center. Acta Radiologica, 2021, 62, 619-627.	1.1	2
320	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2
321	The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children. Turkish Journal of Pediatrics, 2019, 61, 815.	0.6	2
322	Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models. Heliyon, 2022, 8, e09760.	3.2	2
323	Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1212-1214.	0.8	1
324	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 403-405.	1.3	1

#	ARTICLE	IF	CITATIONS
325	Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. Upsala Journal of Medical Sciences, 2016, 121, 196-197.	0.9	1
326	Gastroesophageal reflux and <scp>COPD</scp> exacerbations: Is cholinergicâ€mediated oesophagoâ€bronchial reflex a possible link?. Respirology, 2016, 21, 1496-1497.	2.3	1
327	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 103-112.	2.5	1
328	Anxiety and asthma in youth. Is a stressâ€induced increased cholinergic tone the possible link?. Pediatric Pulmonology, 2018, 53, 128-129.	2.0	1
329	Occupational exposure to furry animals and asthma. Annals of Allergy, Asthma and Immunology, 2018, 121, 512-513.	1.0	1
330	Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ Evidence-Based Medicine, 2018, 23, 183-184.	3.5	1
331	Response. Chest, 2019, 155, 1079-1080.	0.8	1
332	Current long-acting muscarinic antagonists for the treatment of asthma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-15.	1.8	1
333	Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA/LAMA synergy. , 2017, , .		1
334	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
335	Impact of doxofylline in COPD: a pair-wise meta-analysis. , 2018, , .		1
336	Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis. Drugs of the Future, 2019, 44, 845.	0.1	1
337	Cardiovascular disease in COPD. , 2020, , 47-65.		1
338	Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). European Annals of Allergy and Clinical Immunology, 2020, 52, 230.	1.0	1
339	Use of face masks and allergic rhinitis from ragweed: Why mention only total pollen count and not air pollution levels?. International Forum of Allergy and Rhinology, 2022, 12, 886-888.	2.8	1
340	Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. European Annals of Allergy and Clinical Immunology, 2017, 49, 92-96.	1.0	1
341	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. New Microbiologica, 2017, 40, 107-112.	0.1	1
342	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. US Respiratory & Pulmonary Diseases, 2021, 6, 31.	0.2	1

#	ARTICLE	IF	CITATIONS
343	Immunogenesis of Lung Granulomatosis: New Acquisitions. International Journal of Immunopathology and Pharmacology, 1996, 9, 77-77.	2.1	0
344	Multi-Dimensional Assessment in Idiopathic Pulmonary Fibrosis. Chest, 2017, 152, A446.	0.8	0
345	Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. Journal of Occupational Health, 2017, 59, 310-311.	2.1	0
346	Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1808-1809.	3.8	0
347	Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1093-1094.	3.8	0
348	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. International Archives of Allergy and Immunology, 2019, 180, 142-143.	2.1	0
349	CD71 ^{hi} Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1444-1446.	5.6	0
350	Minimalist Thoracoscopic Biopsy of Interstitial Lung Disease. , 2019, , .		0
351	Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. Acta Radiologica, 2020, 61, 204-218.	1.1	0
352	Can placebo challenge test (inducing a "nocebo effect") be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups "Stress-Asthma" and "AAIITO Regione Campania". European Annals of Allergy and Clinical Immunology, 2021, 53, 284.	1.0	0
353	Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. Expert Opinion on Pharmacotherapy, 2021, 22, 943-945.	1.8	0
354	Sex differences in excessive oral corticosteroid exposure in poor adherent adult asthmatics overusing short-acting β_2 -agonists. Minerva Medica, 2021, , .	0.9	0
355	Occupational allergy to horse allergens: More than exposure to horses!. International Journal of Occupational Medicine and Environmental Health, 2016, 29, 721-723.	1.3	0
356	Systemic pharmacotherapy. , 2019, , 215-222.		0
357	Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. AboutOpen, 2019, 6, 55-61.	0.2	0
358	Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 472-473.	1.3	0
359	Anxiety depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link. European Annals of Allergy and Clinical Immunology, 2020, 52, 190-192.	1.0	0
360	PP399 Analysis Of Referral Patterns To Specialized Centers In Idiopathic Pulmonary Fibrosis To Define A New Regional Care Pathway. International Journal of Technology Assessment in Health Care, 2020, 36, 33-33.	0.5	0

#	ARTICLE	IF	CITATIONS
361	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	1.6	0
362	Urgent awake thoroscopic treatment of retained haemothorax associated with respiratory failure. Annals of Translational Medicine, 2015, 3, 112.	1.7	0
363	COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy. European Annals of Allergy and Clinical Immunology, 2022, , .	1.0	0
364	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. Expert Opinion on Pharmacotherapy, 2022, , 1-4.	1.8	0
365	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulmonary Medicine, 2021, 21, 396.	2.0	0
366	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, , 103363.	1.3	0
367	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology, 2022, 15, 269-283.	3.1	0
368	Systematic Literature Review of Treatments Used for Refractory or Unexplained Chronic Cough in Adults. , 2022, , .		0